Whole Pelvis Radiation for Higher-Risk Prostate Cancer May Up Survival
Prophylactic whole pelvis radiation therapy may improve survival in certain patients with prostate cancer.
Prophylactic whole pelvis radiation therapy may improve survival in certain patients with prostate cancer.
The natural history of nonmetastatic castration-resistant prostate cancer (nmCRPC) can serve as a benchmark for advances in imaging and treatment, according to investigators.
Equal access to care may not be sufficient to eliminate racial and ethnic disparities in prostate cancer care, according to investigators.
On univariate analysis, positive vs negative MRI findings were significantly associated with a 3.1-fold higher risk for cancer-specific death, according to investigators.
The perioperative period is receiving increased attention as a platform to inhibit cancer progression, according to investigators.
Study findings suggest a longer ADT duration than NCCN guidelines for patients with high-risk prostate cancer treated with EBRT alone.
There is no universal approach to patient selection for cytoreductive nephrectomy.
Half of urologists order routine urine cytology in patients with low-risk non-muscle-invasive bladder cancer.
Patients with a pT0 tumor at the time of radical cystectomy are still at risk of recurrence and progression and should not be considered cured.
Researchers have questioned whether diabetes exerts adverse effects on the prognosis of RCC.